Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature

Niklas Börschel,Christian Schwöppe,Caroline Zerbst,Linus Angenendt,Torsten Kessler,Wolfram Klapper,Leonardo Giovannoni,Giuliano Elia,Dario Neri,Wolfgang E. Berdel,Rolf M. Mesters,Christoph Schliemann

Leukemia Research（2015）

引用 14|浏览7

暂无评分

摘要

•L19-IL2 is a fully human immunocytokine that targets EDB-Fn positive blood vessels.•L19-IL2 efficiently homes to angiogenic vessels in mantle cell lymphomas (MCL) in mice.•The antibody-mediated accumulation of IL-2 recruits immune cells to the lymphoma tissue.•L19-IL2 strongly potentiates the activity of anti-CD20 immunotherapy against MCL xenografts.•EDB-Fn is expressed in the vasculature of human MCL samples.

查看译文

关键词

Vascular targeting,Mantle cell lymphoma,Immunocytokine,Interleukin-2,Rituximab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要